CD19/CD20 Double Knockout Raji Cell Line

Products from BPS Bioscience require a minimum order value above 400€

Application: Use as a control in CAR-T or NK co-culture killing assays.

Background: The Raji line was established from a Burkitt's lymphoma patient. Raji cells constitutively express B cell antigens CD19, CD20, and CD22, and offer a physiologically relevant platform to evaluate cancer-directed immunotherapies such as Chimeric Antigen Receptor (CAR) T-cells.CD19 (also known as Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) is a glycoprotein expressed on the surface of B lymphocytes through most phases of B cell maturation. It is strictly required for B cell terminal differentiation. Mutations in the CD19 gene cause severe immune-deficiency syndromes associated with impaired antibody production, such as CVID3 (common variable immuno-deficiency 3). The majority of B cell malignancies express normal to high levels of CD19, making it a nearly ideal target for cancer immunotherapy. Blinatumomab, a CD19/CD3 bi-specific T cell engager (BiTE) has been approved for relapsed/refractory B precursor ALL (Acute lymphoblastic leukemia) and CD19 was the target of the first approved CAR-T cell therapy. Studies of CD19 function and expression profiles will continue to broaden our knowledge and support broader applications in cancer therapy. CD20 (also known as B-lymphocyte antigen CD20, or MS4A1) is a non-glycosylated protein expressed on the surface of B-cells during all stages of B-cell development following the pre-B phase. The function and natural ligand of CD20 is not entirely clear. However, CD20 is a marker for several B-cell malignancies, including B-cell lymphomas, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. Accordingly, several anti-CD20 monoclonal antibodies have been developed to effectively deplete B-cell populations and manage B-cell malignancies, as well as some inflammatory and autoimmune diseases. The first anti-CD20 monoclonal antibody was Rituximab, which was approved by the FDA in 1997. More recently, anti-CD20-CD19 bispecific CAR-T cells have been developed to address concerns over potential relapse in cancer patients.

Description: CD19/CD20 Double Knockout Raji Cell Line is a Raji cell line where CD19 (Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) and CD20 (B-lymphocyte antigen CD20, or MS4A1) have been genetically removed from Raji cells using CRISPR/Cas9 genome editing.This cell line has been validated by genome sequencing and flow cytometry.

Host Cell Line: Raji

Storage Stability: Cells will arrive upon dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at support@bpsbioscience.com if the cells are not frozen in dry ice upon arrival.

Supplied As: Each vial contains ˃1 x 10⁶ cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)

Uniprot: CD19: P15391; CD20: P11836

Warnings: Avoid freeze/thaw cycles

Biosafety Level: BSL-2

• Artikelnummer: BPS82623
• Hersteller: BPS Bioscience
• Hersteller Artikelnummer: 82623
• Verpackungseinheit: 2 vials
• Mengeneinheit: PAK
• Wirt: Human